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Glioblastoma Multiforme (GBM) are aggressive tumors of the central nervous system (CNS) that 
are characterized by proliferation and a strong tendency of cancer cells to infiltrate the brain. The 
mechanisms underlying GBM migration involves the degradation and remodeling of the 
extracellular matrix (ECM). Gap junctions are intercellular channels that permit the exchange of 
small metabolites (<1 kDa) between adjacent cells. Gap junction proteins (connexins, Cxs) have 
been shown to promote the in vivo and in vitro invasiveness of GBM. We have demonstrated 
previously connexin43 (Cx43) increases glioma motility and increases the expression of pro-
malignancy factors such as MMP3 and osteopontin. The cellular mechanisms of connexin-induced 
migration are poorly understood. As glioma migration and invasiveness are hallmarks of GBM 
malignancy, we have sought to identify protein-protein interactions and signaling networks 
downstream of Cx43. In this study, we have identified the interaction of Cx43 with annexinA2, a 
calcium-dependent binding protein linked to the increase of cell migration and MMP/protease 
activation. The interaction of Cx43/annexinA2 was identified by Cx43 co-IPs (LC-MS/MS), and 
the proteomic analysis gap junction-enriched fractions (differential centrifugation, and high-
throughput, stable isotope labeling, HPLC-MS/MS) and reciprocal Co-IPs (SDS-PAGE/Western 
blot). As network bioinformatic analysis of Cx43 pathways in glioma predicts increases cell 
motility, we further demonstrate peptide inhibitors down-stream of Cx43/annexinA2 down-
regulates MMP-3 activity (by gelatin zymographic assays) and expression (by Western blot). Our 
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Chapter 1: Introduction 
 
Glioblastoma Multiforme (GBM) 
High-grade brain tumors such as glioblastoma multiforme (GBM) demonstrate a high rate of 
mortality (1). Gliomas are brain tumors that arise from astroglia stem or progenitor cells and are 
responsible for about 30% of all primary brain tumors, and 80% of malignant brain tumors (2). 
Gliomas are the leading cause of death that arise from primary brain tumors (2). Gliomas are 
primarily classified based on their histology, morphology, location, characteristic differentiation 
patterns, and anaplastic features (2, 3). Assignment of glioma grades using the World Health 
Organization system (WHO I – IV) is based upon the presence or absence of anaplastic 
characteristics, with grade IV GBM being the most malignant type (2, 3); marked by aggressive 
growth, necrotic core and microvascular proliferation (4). Despite decades of intense research, 
there is no cure for GBM. GBM presents diffuse and heterogeneous tumor phenotypes that pose 
significant challenges for radio- and chemotherapy. As a result, complete tumor resection is nearly 
impossible because tumors seamlessly integrate with brain parenchyma (5, 6). Indeed, GBM 
typically invades via four main routes through 1) perivascular space, 2) parenchyma, 3) 
subarachnoid space, and 4) white matter tracts (7).  It is not clear if glioma cells use one route 
exclusively or capable of switching between multiple paths. Glioma migration is regulated by 
intrinsic molecular signals and external environmental cues (8). Such mechanisms include the 
release of paracrine signals, extracellular matrix (ECM) remodeling and the releases of enzymes, 
ECM scaffolds, cytokines, and matrikines (8).  
Apart from ECM remodeling, migrating glioma cells represents a dynamic state of 
metabolism, oxygen, and nutrients. The hypoxic conditions within the GBM core activate the 
promigratory transcription factor hypoxia-inducible factor 1 (HIF-1) (9, 10). Several cytokines, 
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chemokines, and proteases that support migration frequently correlate with high motility glioma 
(8). Most notably, ECM proteases enhance of tumor migration and invasion, with corresponding 
changes in the actin cytoskeleton (8). Here, glioma cells typically lose intracellular cell adhesions 
and induce changes in cell morphology that enables the infiltration of the perivascular space (8). 
The interaction of non-neoplastic cells, such as astrocytes or endothelial cells with adjacent glioma 
cells are also essential (11, 12). Astrocytes further support migration by directly interacting with 
gliomas or by releasing additional signaling proteins that further support invasion (13, 14). 
 
The role of Connexins and Gap Junctional Intercellular Communication (GJIC) in 
Migration 
Cell-to-cell interactions play a role in the regulation of cellular processes including development, 
differentiation, cell synchronization, neuronal activity, and immune response (15-17). Gap 
junction (GJ) channels are sites interactions located between adjacent cells that link cytoplasmic 
compartments (18, 19). These plasma membrane contacts making up GJs are readily recognizable 
as a uniform 2-3 nm “gap” (20). The GJ plaque is made up of densely packed ion channels made 
up of connexin proteins. These channels permit the passage of small molecules up to ~ 1000 Da 
(small metabolites, secondary messengers and ions) (21), a process known as gap junction 
intercellular communication (GJIC) (19). The connexins are a 22-member family of integral 
transmembrane proteins, the best know member being connexin43 (Cx43) (21). The half-life of 
connexins is very short (1.5-5 h) (22), with their rapid production and turnover directly linked to 
GJIC levels. Gap junctions are expressed in nearly all excitable and non-excitable tissues. For 
example, cardiac muscles require gap junctions to establish sensitive channels that are essential to 
synchronization (23). Moreover, knockout mice lacking Cx43 have been shown to die shortly after 
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birth, and mutations in Cx43 the cause of human diseases (e.g., oculodentodigital dysplasia). Such 
roles for Cx43 demonstrate the importance and functional significance of intercellular 
communication mediated by GJs (23).  
The link between connexins and cancer has been explored by in vivo studies utilizing 
transgenic and mutant mice. Here, evidence from these studies points towards Cx43 having a 
tumor-suppressing role (i.e., the regulation of cell growth). Cell lines obtained from several tumor 
types typically observe losses in connexin and lack GJIC (18, 24-26). Also, connexin expression 
and GJIC was found to be inhibited by oncogenes and tumor-enhancing reagents (27-29). The 
introduction of connexins in cancer cell lines, as well as overexpression, connexin-knockdown, 
knockout, and knockdown/rescue experiments, provide evidence that supports connexins as a 
potent regulator of tumor growth (30-32). However, new data suggest connexins may also be 
involved in tumor progression, including glioma migration and invasion (30, 34). 
 
Figure 1.1 Cx43 gap junction channel 
Cx43 (A), an integral membrane protein oligomerizes to form a hexamer, known as connexon hemi-gap junction channel (B). The 
oligomerization of Cx43 into a connexon (in the Golgi apparatus) is followed by connexon transport and docking at the plasma membrane. 







Regulation of tumor proliferation is regulated by connexin mechanisms that are dependent 
and independent of GJIC(33). The use of channel-dead mutant and GJIC inhibitors suggests GJIC-
independent mechanisms of Cx43 regulate migration via epithelial-mesenchymal transition (EMT) 
(30, 34). Cx43 expression in MDA-MB-435 cells resulted in the upregulation of markers for the 
mesenchymal state (30). In support of this view, primary human GBMs and normal neural 
progenitors, Cx43 was found to shift these cells towards the mesenchymal state (35).  
Gap junction channel-dependent cell migration mechanisms 
A growing body of evidence suggests GJIC likely plays a role in cell migration (34, 36). The direct 
GJIC between glioma cells and astrocytes modulate gene expression and morphology of astrocytes 
(37, 38). GJIC between glioma and endothelial cells modulates the invasion of GBM (39). In a 
wound healing study involving U251 glioma cells, increased motility correlated with suppressed 
Cx43. Interestingly, when Cx43 was down-regulated in brain slices, the invasion potential of these 
cells was reduced (40).  
Gap junction channel-independent cell migration mechanisms 
There is increasing data suggests migration is facilitated by connexins independently of GJIC in 
some glioma cells (41, 42). The extracellular loop of Cx43 which promotes cell adhesion has been 
shown to regulate neuronal migration in the developing brain (42). In C6 cells, the Cx43 carboxyl 
terminus (CT) increases movement (42), whereas constructs for Cx43 lacking the CT had no effect 
(41). In LN18 human glioma cells, the Cx43CT (257 to 382) is sufficient to increases migration 
(41, 43). The Cx43CT mediates interactions with other proteins to mediate migration (43).  
 
Protein-protein Interactions and Connexins 
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Protein-protein interactions (PPIs) are involved in a range of biological processes, allowing 
proteins to exert their functional roles in a variety of cellular processes (44). PPIs are typically 
formed from non-covalent interfaces contacting proteins (45, 46). Homo- or hetero-oligomeric 
PPIs are based on the constituents of the interacting surfaces, while obligate or non-obligate PPIs 
depends on stability (47). Depending on the persistence of the interacting protein, the PPIs may be 
termed transient or permanent (47). A ‘stable’ protein complex would be the result of high-affinity 
coupling (47). PPIs are essential to the function of the cell as the functional role of proteins. Over 
80% of proteins operate as complexes rather than on their own (48). As highlighted by Phizicky 
and Fields (49), PPIs play several critical roles that influence biology (48). As such, PPIs of Cx43 
may regulate migration via the modification of enzyme kinetics/specificity of a substrate, binding 
of cytoskeletal components, regulation of actin dynamics, regulation of the plasma membrane, and 
the propagation of signals that induce glioma migration. Several recent advances have allowed 
researchers to acquire high-throughput protein interaction data through affinity-purification mass 
spectrometry (AP-MS) (50, 51). These advances provide avenues for the isolation of protein 
complexes to characterize constituent proteins (50) using the AP-MS approach.  
 
Glioma migration and the ECM  
Pseudopalisading cells are a constant feature of GBM that are associated with tumor necrosis (52).  
A characteristic of GBM is a very necrotic core that is surrounding by cells with low oxygen and 
nutrient levels. Mesenchymal to epithelial transition is believed to be regulated by the availability 
of oxygen and nutrients at the tumor (9). It is widely speculated gliomas trigger migration to escape 
hypoxia (52). In hypoxic or nutrient deficient conditions, for example, tumor cells seek favorable 
environments (9). In response to hypoxia, gliomas activate certain pro-migratory signals like 
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metalloproteases, galectins, EMT transcriptional regulators such as SLUG and SNAIL, and 
CXCR4 and CXCR7 (53). CXCR7 is involved with stromal-derived factor (SDF)-1α/CXCL12 
during glioma migration (54, 55). Several key enzymes are critical to ECM remodeling including 
several matrix metalloproteases (MMPs), the serine protease, plasmin, cathepsins, and tissue 
plasminogen activator (56). The density, rigidity, and geometry of the ECM also play important 
roles (56).  Here, ECM stiffness supports the formation of stress fibers and focal adhesions that 
ultimately aid migration.  
Matrix metalloproteinases (MMPs) 
MMPs comprise a large family of zinc-dependent endopeptidases which are either secreted or 
attached to the cell membrane (57). They are synthesized as the inactive zymogens with a signal 
peptide attached to their propeptide domain for translocation to the membrane or secreted out of 
the cell. Collectively, MMPs degrade and activate remodeling of the ECM (58). In glioma, MMPs 
expression is very high compared to normal brain, with MMP-2 and MMP-9 interacting with pro-
migratory transforming growth factor (TGF-β) leading to the activation of MMP-2 (58). MMP-3 
is associated with glioma invasion since they are overexpressed in invading cells. MMPs are 
synthesized as inactive zymogens, requiring the removal of the inhibitory prodomain (59). In many 
cancers, there is a positive correlation between tumor invasive and metastatic potential and MMP 
expression levels.  
Activity of MMPs may be detected zymography (59-62). The method is based on standard SDS-
PAGE that is supplemented with substrate protein (such as gelatin or casein). After removal of the 
SDS, MMPs renature within the polymerized gel to exert their proteolytic activity and 














1.1 Thesis rational and objectives 
1.1.1 Identification of Cx43 protein-protein interactions in glioma migration 
GBM are lethal tumors that are characterized by a highly infiltrative growth of tumor cells into the 
healthy brain cells. The median survival for GBM is only 14 months even with surgical resection, 
chemotherapy, and irradiation (63). Our understanding of Cx43 networks is still very limited and 






Figure 1.2 MMP-3 representative structure 
MMP-3 also known as stromelysin 1 is synthesized as the inactive zymogens and activated by the cleavage of the 





The overall hypothesis of this study is that Cx43 interacts with Annexin A2, and this 
Cx43/Annexin A2 interaction regulates migration of high-grade glioma cells.  
The aims of this thesis are to 1) identify the signaling pathways of Cx43-induced migration, and 















Chapter 2: Materials and methods 
2.1 Cell cultures 
Rat C6 and C6-13 glioma cells were cultured in 4.5mg/ml Dulbecco’s modified Eagle medium 
(DMEM) supplemented with 10% fetal bovine serum (FBS) and 1X penicillin-streptomycin (PS) 
antibiotics. The C6-13 glioma cells used in the study overexpress Cx43. To screen out cells with 
none or reduced Cx43, a protocol selecting for only C6-13 (Cx43 over-expressing cells) was 
incorporated in cell cultures for C6-13 only. Briefly, 106 C6-13 cells were seeded in a 100mm 
culture dish containing DMEM containing 5% FBS and 1X PS and allowed to grow for 24 hours. 
Cells were trypsinized three days later, and GPT selection reagent (500X mycophenolic acid; 100X 
Aminopterin, Millipore/Sigma) was added to 5 x 105 cells in fresh medium to a final concentration 
of 1X. After 24 hours, media was aspirated, and fresh medium containing the same concentration 
of GPT selection reagent. This process was repeated every three days until C6-13 colonies formed. 
Cells were incubated at 37°C with 4% CO2. Media was changed regularly to provide fresh 
nutrients, remove debris, and control contamination. Cells were passed by removing old media 
and rinsing in 1X PBS and then trypsinized and passed. 
2.2 Bioinformatics analysis 
2.2.1 Data 
Data from previous Cx43 protein-protein interactions study done by Chen et al (51) was extracted 
from BioGRID database. This data was generated from affinity purification coupled with mass 
spectrometry (AP-MS), and contained 110 proteins associating with Cx43. Analysis of gap 
junction-enriched membrane preparations, using the LTQ Orbitrap mass spectrometer, resulted in 
the identification of 1680 proteins. These sets of protein data, constituting two protein groups from 






2.2.2 Gap junction-enriched plasma membrane preparation 
Gap junction-enriched plasma membranes were isolated by modifying the method described here 
(64). C6 and C6-13 cells were removed from the incubator and immediately placed on ice. They 
were then harvested by removing growth media and rinsing the cells with 1X PBS. PBS rinse was 
repeated two more times. Thereafter, any leftover PBS was completely removed by pipetting while 
tilting the culture dish. 1 ml of cold gap junction buffer (5mM Tris-HCl, 5mM EDTA, 5mM 
EGTA; pH = 8.0) containing 1mM PMSF was added to the culture dish and adherent cells were 
Figure 2.1 Experimental workflow and overview of bioinformatics and proteomics analyses, validations, and functional analysis. 
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scraped into buffer and transferred into a pre-chilled dounce homogenizer. Cells were 
homogenized by 40-50 strokes of the dounce and transferred to a pre-chilled microcentrifuge tube. 
It is critical that all membrane preparations be done at 4°C to avoid significant protein loss. 
Samples were then briefly sonicated for 10 -15 seconds and spun in a cold centrifuge at 1000 g for 
10 minutes to pellet nuclei and other cell debris. The supernatant was transferred to a cold 
microcentrifuge tube and centrifuged for 1 hour at 30 000 g and 4°C. Protein pellets were gently 
rinsed with fresh cold gap junction buffer and allowed to dry in the cold with inversion of the tube. 
 
 
2.2.3 Peptide sample preparation  
Gap junction-enriched protein pellet was solubilized in digestion buffer (1% deoxycholate, 
50mM NH4HCO3). Protein concentrations of C6 and C6-13 samples were normalized from BCA 
analysis and then heated for 5 – 10 minutes in 99°C. Sample volume were kepted as small as 
possible for protein digestion (~100 µL). Proteins were reduced using DTT (1:50, mass DTT:mass 
protein) and then incubated for 30 minutes at 37°C, and then alkylated IAA (1:10) and incubated 
20 minutes at 37°C. Samples were digested by adding trypsin at a ratio of 1:50 and incubated 
overnight at 37°C. Peptides were recovered by doubling the reaction volume with sample buffer 
Figure 2.2 Isolation of gap junction-enriched protein complexes 
Plasma membrane protein complexes are isolated by mechanical disruption of whole cells, in ice-cold GJ buffer, by applying gentle 
strokes in a dounce homogenizer. The plasma membrane pellet is then obtained by differential centrifugation. 
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(0.5% acetic acid) and centrifuging at maximum speed for 3 minutes to remove deoxycholate. The 
supernatant was collected for analysis. 
2.2.4 Peptide dimethylation 
Peptides from C6 and C6-13 were isotopically labeled by reductive dimethylation as described 
previously (65). Stage-tipped and dried peptides were re-dissolved in 40 µl of 100mM 
triethylammonium bicarbonate (TEAB) and sonicated for 5 minutes. Light formaldehyde 
isotopologue (200 mM CH20 (L)) was added to C6 peptides while medium (200 mM CD20 (M)) 
was added to C6-13 peptides. Samples were sonicated for 5 minutes. Correspondingly, 4 µl of 
0.6M light cyanoborohydride and 0.6M medium cyanoborohydride was added to the light and 
medium peptides. At this point, samples were spun and left in ambient temperature in the dark for 
at least 6 hours to overnight. 40 µl of 3M NH4Cl was then added to the samples and left at ambient 
temperature for 10 minutes in the dark. To degrade sodium cyanoborohydride, the sample volume 
is quadrupled by adding sample buffer and allow to stand for at least 1 hour. Mix labeled peptide 
samples together, reduce sample volume to almost dry and re-suspend in 100 µl of sample buffer 
and proceed to stage-tipping. 
2.2.5 LC-MS/MS 
 Before loading peptide samples in mass spectrometer, they are again desalted and purified 
by STAGE-Tip. C18 discs made into a small column in a P200 tip was first activated by Buffer B 
(0.5% acetic acid, 80% acetonitrile) and sample buffer (0.5% acetic acid, 0.1% Formic acid) 
respectively. Peptides were then bound to the reverse phase C18, then washed with sample buffer, 
and eluted with sample B. Eluted peptides were air dried using a vacuum centrifuge and re-
dissolved in 10 µl of sample buffer. Peptides were separated using an Agilent 1200 series HPLC 
connected to a nanoelectrospray ionization (nano-ESI) source. They were loaded and separated in 
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C18 mobile phase packed in chromatographic columns that were made from fused silica 
capillaries. HPLC-MS was run in Agilent 6530 QTOF, operated in data-dependent acquisition 
(DDA) mode, resulting in 1 full MS scan and 5 MS/MS scans while allowing the instrument to 
dynamically check for exclusions of MS/MS that has been acquired already.  
2.2.6 Protein Identification 
 Protein identification was performed using MASCOT (Matrix Science). Raw Agilent (.d) 
files were first converted to their corresponding mgf files and exported to MASCOT. The program 
was run using the following options. Enzyme: trypsin/P, Database: UniProt rat, Precursor mass 
tolerance: 20 ppm, Fragment mass tolerance: 0.6 Da, Fixed modification: Carbamidomethyl (C), 
Variable modification: Dimethyl (K), Dimethyl (N-term), Dimethyl: 2H (4) K, Dimethyl: 2H (4) 
(N-term), and oxidation (M). 
2.2.7 Peptide quantification 
 The relative quantification of labeled peptides was done using Skyline (66). For 
quantification, dimethylated peptides, light (L) and medium (M) were set to +28.031 Da and 
+32.056 Da and was based on all modified peptides. Protein IDs from MASCOT were exported 
to Skyline, for spectral library generation. Skyline then uses the library’s peptide retention time 
(RT) information to extract chromatograms from raw (.d) Agilent LC-MS/MS run files. In this 
case, chromatograms were extracted within a 2- to 3-minute window around actual peptide RT. 
Peptide intensity values for L and M was obtained, and fold change calculated for each protein 
based on the average of all peptides intensities identifying the protein. 
2.2.8 Functional analysis of protein groups 
A list of protein IDs was generated from each of the protein groups above and saved as two separate 
text files – one for Cx43 interacting data, and the other for Gap junction-enriched membrane 
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proteins. The protein IDs for each list was first converted to make all proteins compatible with the 
analysis tool using the Gene ID conversion tool in DAVID (67). To analyze proteins common to 
both lists, we generated a Venn diagram using FunRich v3.1.3 (68) with its database set to UniProt. 
For the Gap-junction enriched protein list, the molecular function, biological processes, and 
cellular localization were analyzed with the gene enrichment tool in FunRich (68). High 
throughput validation of Cx43 interaction networks was done by analyzing the functional 
clustering of proteins in both lists. The Cx43 interaction protein list and the protein list from the 
membrane preparation were exported into FunRich. The protein networks for both sets of proteins 
were generated using the interactive tools in FunRich. FunRich analysis results were exported or 
saved either as graphic or text, excel files. 
2.2.9 Protein validation by SDS-PAGE/western blots 
Cells were washed 3 times in cold 1X PBS in a 100 mm culture dish. 1 ml of cold 
radioimmunoprecipitation (RIPA) buffer (150mM NaCl, 1% Triton X-100, 0.5% sodium 
deoxycholate, 0.1% SDS, 50mM Tris, pH = 8.0) supplemented with 1 mM PMSF was added to 
the culture dish, and adherent cells were collected by scraping into the buffer and transferred to a 
pre-chilled microcentrifuge tube. The sample was quickly pipetted back and forth and allowed to 
incubate on ice for 20 minutes. Homogenate was then centrifuged at 13 000 g for 15 minutes at 
+4°C. 5X gel loading buffer was added to the lysate to a final concentration of 1X and samples 
were heated to 95°C for 5 minutes. For very small and critical samples, the microcentrifuge cap 
was sealed with paraffin to avoid sample losses from heating (bumping). 30 µg of the sample was 
then loaded to each well of a 10% SDS gel and ran in gel running buffer. To estimate the relative 
size of target proteins, 5 µl of pertained protein molecular weight marker (Biobasic, 10-175 kDa 
range) was loaded in the gel. Voltage was set to 60V until proteins reached the resolving gel and 
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after that increased to 120 V until the gel front reached the end of the gel. SDS gel was briefly 
rinsed in deionized water and placed in transfer buffer. Proteins were transferred from the gel to a 
PVDF membrane, in an X-Cell II Blot Module (Invitrogen) transfer system, for 3 hours at 30 V in 
+4°C. Protein transfer efficiency was monitored by Coomassie gel staining. The membrane was 
carefully removed from the transfer and incubated in blocking buffer (5% milk in TBS-T) for 1 
hour at RT. Membrane was washed three times, in wash buffer (20 mM Tris, 150 mM NaCl, 0.1% 
Tween 20), for 5 minutes each and then incubated overnight in 4°C in rabbit Annexin A2 primary 
antibody (Cell Signaling) at 1: 1000 dilution in 1% milk-TBS-T. The membrane was then washed 
and incubated for 1 hour at RT in Rabbit anti- at 1:2000 dilution in 1% milk-TBS-T. After washing 
the membrane, molecular weight marker positions were annotated with Markerglow, our in-house 
protein visualization tool. Membrane was then developed in ECL reagent and scanned in LICOR 
C-DiGiT scanner. For some membranes, we perform strip and reprobe steps. Here, the membrane 
was removed from the scanner and washed briefly in wash buffer. Stripping was done with a 
modified version of Abcam’s mild stripping protocol (0.2M glycine, 0.1% SDS, 1% Tween-20, 
pH = 2.2) and incubated at RT in a rotary shaker for 30 minutes twice for a total of 1 hour. The 
membranes were then washed with PBS for 10 minutes twice. PBS was discarded and was washed 
further with PBS-T twice at 5 minutes each. Membranes were then placed in blocking buffer and 
reprobed for Cx43 and GAPDH as previously described. Rabbit monoclonal anti-Cx43 and anti-
GAPD (both from Cell Signaling) were diluted in 1% milk-TBST at 1:1000. Mouse monoclonal 




2.2.10 Gelatin zymography 
Conditioned media from C6 and C6-13 cells grown in 100 mm culture plates were collected and 
quickly placed on ice. Secretomes were concentrated in a 30 kDa MWCO centrifugal filter and the 
concentrated secretome transferred to pre-chilled microcentrifuge tubes. Protein concentration for 
C6 and C6-13 secretomes was normalized from BCA quantification. Non-reducing SDS loading 
buffer was added to the samples, without boiling, and 50 µg of secretome proteins were loaded 
into the wells of the 10% SDS gel containing 0.1% gelatin and ran as previously described. 
2.3 Functional inhibition assays of Annexin A2-S100A10 peptides 
N-terminal Annexin A2 peptides (69-71) derived from residues 1-14 of Annexin A2, along with 
their scrambled control peptides were ordered from Peptide 2.0. Peptides were delivered as 
trifluoroacetic acid (TFA) salts with a complete data analysis report (Appendices A-D).  
2.3.1 Annexin A2-S100A10 peptide inhibition zymography  
C6 13 cells were incubated with 100µM of small Annexin A2 peptides in serum-free media in 6-
well plates. Secretomes of treated cells along their corresponding non-treated control secretomes 
were harvested after 24 hours of incubation in conditioned media. The serum-free media was 
concentrated by filtering in 30 kDa MWCO centrifugal filters. Secretome samples were transferred 
to a pre-chilled microcentrifuge tube, and zymography was performed as previously described. 
Coomassie-stained zymography gels was then photographed, and the gel was stored in 2% acetic 
acid. Gel images were exported to ImageJ software, and proteolytic bands were analyzed for signal 
intensity. 
2.3.2 Annexin A2-S100A10 peptide inhibition western blots  
C6-13 cells were grown in serum-free media containing 100µM of Annexin A2 N-terminal 
peptides. Treated secretomes along with the negative controls were harvested after 24 hours. The 
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serum-free media was then precipitated by cold acetone (-20°C) as described previously. The 
protein pellets were then solubilized in SDS loading buffer prior to total protein concentration 
determination using BCA. Samples were loaded into the wells of a 10% SDS gel and 
electrophoresis and western blotting were done as described previously. For western blots, rabbit 
monoclonal anti-MMP-3 (Cell Signaling) was used at a dilution of 1:1000 in 1% milk in TBS-T. 
2.4 Co-immunoprecipitation (Co-IP) 
C6-13 glioma cells were grown in 3 x 10 mm culture plates in DMEM containing 10% FBS and 
antibiotics until about 90% confluent. Media was removed from culture plates and cells were 
washed 3 times with cold 1X PBS. 1 ml of cold immunoprecipitation buffer (20mM Tris, 137mM 
NaCl, 2mM EDTA, 1% Triton X-100, 10% glycerol, pH = 8.0), containing 1mM PMSF, was 
added to each plate and cells were scraped off and collected in pre-chilled microcentrifuge tube. 
Cells were incubated for 30 minutes with gentle agitation by pipetting back and forth on ice. After 
incubation, cells were centrifuged at 4°C for 15 minutes at 13000 g. 400 µl of the supernatant was 
then transferred to each of 2 microcentrifuge tubes, one tube for IP and the other for IP negative 
analysis. The rest of the supernatant was saved for IP positive loading. Two µg of mouse 
monoclonal anti-Annexin A2 (Cell Signaling Technologies) was added to IP microcentrifuge tube 
and incubated end over end in a tube roller overnight at 4°C. IP positive and IP negative samples 
following the same procedures except, in IP negative sample, anti-Annexin A2 antibodies were 
excluded. 30 µl of a 50% Protein A resin slurry was added to both tubes and incubated overnight 
at 4°C. Unbound proteins were removed by careful pipetting and beads were washed three times 
by centrifuging at 16000 g for 2 seconds. 1 ml ice-cold PBS was then added for a final wash and 
beads were pelleted. For western blot analysis, Annexin A2-IP pellet and the corresponding control 
samples were suspended in SDS loading buffer, heated to 95C for 5 minutes and loaded into a 10 
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% SDS gel and electrophoresis was performed as previously described. After protein transfer to 
PVDF membrane, probing for Cx43 from Annexin A2 IP proteins was done using rabbit 
monoclonal ant-Cx43 (Cell Signaling) at 1:1000 dilution as previously described. 
2.5 Statistical analysis 
All experiments in this thesis were performed in triplicates with multiple replicates, typically N = 
3. Statistical analysis was done by calculating p-values with the Student’s t-test. Results were 
considered statistically significant for p < 0.05. 
2.6 Zymography 
2.6.1 Secretome protein preparation 
2.5 x 105 rat C6-13 glioma cells were seeded in a 6-well tissue culture plate. Cells were 
grown with regular media change until they reached 80-90% confluency. Growth media was 
aspirated, and cells were briefly rinsed with fresh conditioning media. After that, fresh 
conditioning media was added, and cells were incubated for 24 hours. Conditioned media was 
aspirated from the cell culture dish and transferred immediately to pre-chilled 5ml Pall Microsep 
Advance centrifugal filters, with a 30 kDa molecular weight cut-off. Samples were placed a 
refrigerated centrifuge and spun at 4800 g for 12 minutes at 4°C. This process was repeated until 
the conditioned media volume was reduced by 10x. Concentrated secretome proteins were then 
transferred to pre-chilled microtubes. Secretome protein concentration was determined by 
bicinchoninic acid (BCA) assay. 
2.6.2 Acetone precipitation of secretome proteins 
Conditioned media was aspirated from cell cultures as above but transferred to pre-chilled 
15 ml falcon tubes. Tubes were then placed on ice. Cold acetone (-20°C) was then added to 
conditioned media in a 1:4 ratio, 1 part sample to 4 parts cold acetone. Cold acetone is critical for 
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protein precipitation to obtain best results. The tubes were then placed in -20°C for 1 hour for 
precipitation. Samples were placed in a cold centrifuge and spun at 4800 g for 12 minutes at 4°C. 
Acetone was discarded by tilting the tube slightly and allowed it to drain gently, taking care not to 
lose the protein pellet in the bottom of the tube. Tubes were inverted over Kim wipes to completely 
dry the protein pellet in 4°C to prevent any sample loss. After that, secretome protein concentration 
was determined, as above, by BCA. 
2.6.3 Gelatin zymography 
Gelatin zymography (59-62) was performed by diluting concentrated (filtered) secretome 
in an appropriate volume of non-denaturating 5X SDS loading buffer. Acetone precipitation 
protein pellet was carefully solubilized in the same SDS buffer by slowly working the pellet into 
the buffer with a P200 pipette tip. Samples were allowed to stand at room temperature for 15 
minutes. 5-30µg of secretome protein was loaded in each well of a 10% SDS-PAGE gel that has 
been supplemented with 0.1% gelatin. The gel was run in regular SDS running buffer at 125V in 
+4°C until gel front completely reached the end of the gel. The gel was removed from the 
electrophoresis apparatus and rinsed in deionized water. The gel is then washed twice for 40 
minutes at room temperature (RT) in wash buffer (2.5% Triton-X100 in renaturation buffer). This 
wash step, to remove SDS in the gel, is critical for MMP renaturation. After washing, gel was 
rinsed for 10 minutes in renaturation buffer (50mM Tris-HCl, pH = 7.5, 5mM CaCl2, 1µM ZnCl2, 
0.02% Brij-35, 0.02% NaN3). The zymography gel was placed in renaturation buffer in a sealed 
container, making sure gel is thoroughly covered in buffer and incubated for at least 24 hours in 
37°C. The gel was stained after incubation for 30 minutes to 1 hour in 0.5% Coomassie G250 and 
then destained with destaining solution (10% glacial acetic acid, 40% methanol) until clear bands 
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start to appear. The zymography gel was photographed or scanned before storing in 2% glacial 
acetic acid. 
2.6.4 Results and Discussion 
Gelatin zymography is a very functional and sensitive method for detecting the activity of 
proteases, combining gelatin-infused SDS-PAGE with Coomassie blue staining for easy detection 
of white proteolytic protein bands. However, protein sample preparation is critical to achieving the 
detection of MMPs. As shown in Figure 2.3A, acetone precipitation of secretome proteins resulted 
in the detection of sharp and well-defined bands compared to the MWCO filter secretome 
preparation, even though the loaded protein concentration was the same for both. ProMMP-3 was 
also detected for acetone precipitated sample, suggesting a better resolution than the filtered 
samples. As zymography is a semi-quantitative technique, MMP-3 at various protein loading 
concentrations shows that the acetone precipitation technique performs well, if not better than 













Figure 2.3 Evaluation of secretome sample preparation methods for zymography 
(A) C6-Cx43 cells were treated with small peptides and incubated for 24 hr. Secretomes were harvested from cells and concentrated using a 30 kDa 
MWCO filter, and then analyzed for MMP activity. Secretomes were obtained as in filter concentration, except that they were precipitated with ice-
cold acetone instead of MWCO filter. For both filtered and precipitated samples, the amount of protein loaded to zymography gel wells was the same 
for MWCO filter preparation and acetone precipitation. In (B), increasing concentrations of acetone precipitated secretome proteins were loaded to 





Chapter 3: Results 
3.1 High throughput orthogonal validation of Cx43 protein networks 
3.1.1 Protein enrichment analysis  
To investigate the AP-MS Cx43 interaction and gap junction-enriched protein data, initial data 
processing and functional gene enrichment analysis were implemented. Current advances in the 
development of techniques and methods for the analysis of protein-protein interaction data has led 
to the production of tremendous amounts of protein interaction data (55). In most cases, these are 
























Figure 3.1 Analysis of Cx43-associated proteins. 
(A), Venn diagram comparison of proteins in Cx43-interactions AP-MS data and protein data from GJ-enriched plasma 
membrane. GJ-enriched protein data provides a first line validation for the AP-MS proteins that were found in both sets 
(purple). Protein enrichment analysis for the GJ-enriched proteins shows molecular function (B) and biological 
processes (C) related to glioma cell migration signaling. 
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 To validate the high-throughput AP-MS Cx43 interaction data, gap-junction-enriched 
membrane protein data was obtained by differential centrifugation and analyzed. The results show 
proteins that are unique to both sets of data, representing about 50% of the Cx43 interaction data 
set (Figure 3.1A). Annexin A2 was shown to be present in both Cx43 interaction data and GJ-
enriched plasma membrane protein data. Gene enrichment analysis for molecular function and 
biological process reveals proteins enriched for pathways related to glioma migration and cell 
signaling proteins and molecules, including GTPases activity, cytoskeletal remodeling, integrin 
binding, and other related enriched terms (Figure 3.1). All reported enriched pathways were 
statistically significant (p<0.05). The Cx43 interaction data used in this analysis was obtained from 













Figure 3.2 Network analysis of Cx43-interaction data and GJ-enriched plasma membrane proteins 
Functional clustering of Cx43 proteins (A) was done using FunRich v.3.1.3. Cx43 (red dot, blue arrow) interacting proteins (green dots) forms a single large 
cluster as expected. (B) GJ-enriched proteins formed several clusters, including the main cluster for cx43 interactions. Annexin A2 (blue dot, red arrow) is 
pulled out of the Cx43 cluster for emphasis. Only clusters with calculated statistical significance, p<0.05, are shown. 
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3.1.2 Cx43 interaction network clustering 
The identification of proteins that are present in both Cx43 interaction data and the gap junction 
membrane data gives a quick indication that interacting proteins in the AP-MS data could be 
captured by gap junction enrichment of the plasma membrane. To investigate, the two set of data 
were subjected to network analysis to obtain their functional clustering patterns. As shown in 
Figure 3.2B, the network analysis reveals a Cx43 cluster (Figure 3.2A) within the many clusters 
obtained for the gap junction enriched membrane proteins. Network clustering analysis also shows 
Annexin A2 interactions with members of Cx43 interaction dataset. 
 
3.1.3 Quantitative proteomics reveals a positive regulation of Annexin A2 in C6-13 
glioma cells 
To compare the expression of plasma membrane proteins of C6-13 and wild type C6 
glioma cells. Lysates from C6 and C6-13 glioma cells were digested by trypsin to obtain the 
corresponding peptides. Peptides were labeled by dimethylation. The C6 peptides were labeled 
with light (L) isotopes while the C6-13 peptides were labeled with medium (M) isotopes, and 
analyzed by LC-MS/MS. Several proteins showed markedly significant enrichment, calculated 
from their peptide intensity ratios, including Annexin A2, S100A10, Ahnak, and Calnexin (Figure 
3.3A-D). Peptide quantification ratio for medium labeled (M) Annexin A2 peptides to the light (L) 
peptides were shown to be significantly upregulated in Cx43-overexpressing glioma cells as shown 













Figure 3.3 Identification and quantification of Cx43-associated proteins 
Analysis of gap junction-enriched membrane preparations resulted in the identification of proteins involved in Annexin A2 binding 
complex. Peptide fragmentation of Calnexin (A), Ahnak (B), S100A10 (C) and Annexin A2 (D) are shown. (E) Extracted 
chromatograms for Annexin A2, from labeled peptide quantification analysis, shows upregulation of Annexin A2 in C613 cells 






3.2 Western blot validation of Annexin A2 upregulation 
3.2.1 Annexin A2 upregulation  
The quantitation data for Annexin A2 showed its upregulation in C6-13 glioma cells 
compared to the wild type cells. To further validate this, western blot analysis was performed. 
Briefly, C6 and C6-13 whole cell lysates (WCL), cytosolic soluble proteins, and gap junction-
enriched membranes were obtained. The sample preparations were loaded in triplicates to a 10% 
SDS gel and proteins were separated by electrophoresis. Proteins were then transferred to a PVDF 
membrane and probed with antibodies. The proteins of interest were detected by scanning the 
chemiluminescence obtained from the reaction of the HRP-linked secondary antibody with ECL 
reagent (substrate). 
Analysis of Annexin A2 protein bands at 37 kDa using ImageJ software showed the 
upregulation of Annexin A2 in C6-13 glioma cells compared to control cells (C6 wild type) across 
all sample preparations. As shown in Figure 3.4, the upregulation of Annexin A2 in C6-13 plasma 
membrane was statistically significant. Results for Annexin A2 upregulation for the cytosolic 
portion shows the same trend as that for plasma membrane even though not statistically significant 
(Figure 3.4). 
3.2.2 Gap junction enrichment  
 Gap junction-enriched plasma membrane proteins were obtained by differentiation. 
Briefly, C6-13 and the corresponding control wild type cells were homogenized in GJ buffer and 
nuclei and other cell debris were pelleted. The supernatant was transferred to a new 




To demonstrate gap junction enrichment, the PVDF membrane was subsequently probed 
for Cx43 and GAPDH.  
 
Figure 3.4 Western blot validation of Annexin A2/Cx43 upregulation in plasma membranes of C6-13 gliomas. 
C6 and C6-13 cells were prepared in 3 ways. The GJ-enriched membrane portions were obtained by homogenizing in GJ and pelleted by differential 
centrifugation. WCL were obtained by homogenizing cells in the same buffer and briefly spinning to remove debris and nuclei, and cytosolic sample 
were obtained by recovering the soluble portions from WCL. Proteins transferred to PVDF membrane were probed for Annexin A2. To check for GJ-
enrichment, membranes were reprobed with Cx43 and GAPDH primary antibodies to capture not only protein expression levels, but also their 





Correctly folded Cx43 in the endoplasmic reticulum are trafficked to the Golgi apparatus where it 
dimerizes and eventually docked at the plasma membrane (19, 20). Cx43 functions on the cell 
membrane are controlled largely by phosphorylation (51). As shown in Figure 3.4, there is a high 
expression of Cx43 in the C6-13 plasma membrane compared to the cytosolic portion. As 
expected, there is an inverse correlation of GAPDH expression to that of Cx43 in plasma 
membrane versus cytosol (Figure 3.4). As a further validation for the enrichment of Cx43 in the 
plasma membrane, the Cx43 bands reveals several levels of phosphorylation as shown by the 
multiple band shift towards higher molecular weights in the figure.  For C6 glioma cells, the low 
GAPDH expression also indicates enrichment for plasma membrane proteins; however, due to its 
low expression levels in C6 glioma cells, Cx43 is not detected.  
3.2.3 Annexin A2 distribution in glioma cells 
Annexin A2 can regulate different biological processes in the cell depending on whether it is in 
the cytoplasm or located on the cell surface (72). Annexin A2 trafficking to the plasma membrane 
surface is mediated by the presence of cytoplasmic calcium ions, and phosphorylation (72). The 
distribution of Annexin A2 in C6 and C6-13 glioma cells is shown in Figure 3.4. In C6-13 cells,  ̴ 
65% of total Annexin A2 expression occurred in the plasma membrane.   
3.3 Co-IP analysis 
The increased binding of Annexin A2 to S100A10 on the plasma membrane activates the binding 
of other proteins leading up to the release of plasmin and MMPs that are involved in ECM 
degradation and remodeling (73, 74). So far, Annexin A2 has been consistently shown to be up-
regulated in C6 gliomas overexpressing Cx43 form both quantitative proteomic data and western 
blot validations. Specifically, differential centrifugation membrane preparations (64) shows 
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enrichment of gap junction protein complexes at in plasma membrane. In the same vein, Annexin 
A2 has been shown, here, to be significantly upregulated in C6-13 plasma membrane relative to 
the control of glioma cells. In light of the results obtained thus far, and on the basis that Cx43 may 
be involved in the differential expression of Annexin A2, the interaction of Cx43 with Annexin 
A2 and the underlying mechanisms was examined next. 
 
 
Figure 3.5 Annexin A2 CoIP analysis of C6-13 gliomas. 
Annexin A2 IP was performed using C6-13 cells. Lysates were immunoprecipitated with mouse primary Annexin A2 antibody and 
analyzed by SDS-PAGE, and then transferred to a PVDF membrane. The membrane was then probed with rabbit primary Cx43. 
Note the heavy Cx43 bands (lanes 4-6) and Cx43 bands in WCL (positive control, lanes 1-3). IgG addition to lysate without 
Annexin A2 antibody, served as negative control (lanes 7 and 8). 
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C6-13 cell lysates were prepared in non-denaturing IP buffer and analyzed by Annexin A2 IP for 
Cx43 detection. Immuno-precipitated protein complexes were run in SDS-PAGE and transferred 
to a PVDF membrane. To validate Cx43 interaction, the membrane containing separated Annexin 
A2 IP proteins was probed with Cx43 antibodies. As shown in Figure 3.5, Cx43 bands can be seen 
at   ̴43 kDa, with phosphorylated bands appearing at a higher molecular weight. Interestingly, 
phosphorylated Cx43 bands previously obtained for the gap junction enrichment analysis (Figures 
3.4 and 3.5) closely resembles that from Cx43 western blot validations of Annexin A2 IP. 
3.4 Comparative analysis of MMP-3 activity in C6 and C6-13 gliomas 
MMP-3 belongs to the matrix metalloproteinases family of proteins that are synthesized as 
an inactive zymogen and become active upon cleavage of a propeptide group that allows access to 
the catalytic site containing a zinc ion (58). The choice of C6-Cx43 cells for experiments was 
based on its well-established model of glioma cell migration, where increased Cx43 expressed 
directly correlates with increased glioma cell migration. However, the exact role for MMP-3 in 
this model and its activation and contributions to the mechanisms that enhance migration, in this 
case, needed to be explored. 
 To investigate MMP-3 activity, conditioned media from C6 and C6-13 glioma cells were 
analyzed by gelatin zymography. Coomassie-stained gels were scanned and MMP-3 proteolytic 
bands were analyzed. As shown in Figure 3.6B, there was significant up-regulation of MMP-3 in 






As a second layer of evidence of MMP-3 upregulation in C6-13 gliomas, western blot analysis of 
secretomes of C6 and C6 13 was performed. The results (Figure 3.6A) further validates the 
evidence obtained from MMP-3 zymography. These results are further described in the following 
manuscript (75). 
 
3.5 Functional analysis of Annexin A2-S100A10 complex inhibition  
3.5.1 Effect of Annexin A2-S100A10 inhibition on MMP-3 activity 
So far, evidence from quantitative proteomic data as well as western blot and zymography points 
to the regulation of Annexin A2, especially on the plasma membrane. Secretome analysis indicates 
the activation of MMP-3 in C6-Cx43 glioma cell model relative to the wild type while the Annexin 
A2 IP data reveals and interaction between Cx43 and Annexin A2. To further explore the data that 
has been obtained so far to understand their contributions to the signaling of glioma migration 
pathways, functional analysis of Annexin A2-treated cells was performed. Here, C6-Cx43 glioma 
Figure 3.6 Comparative analysis of MMP-3 expression in C6 and C6-13 secretomes 
Conditioned media (CM) from C6 and C6-13 were analyzed by western blot (A) and gelatin zymography (B). Secretome proteins 
transferred to a PVDF membrane were probed with rabbit primary MMP-3 antibody. For zymography, proteins were separated in 
SDS gel containing 0.1% gelatin. Zymography gel images were processed in ImageJ software. 
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cells were treated with N-terminal Annexin A2 peptides and their scrambled controls. These 
peptides (69-71) were expected to competitively block the S100A10 binding sites for Annexin A2 
thereby inhibiting the pathway for plasmin production. As the degradation and remodeling of the 
ECM occurs with increased activation of MMPs (58), MMP-3 zymography of secretome from C6-
13 glioma cells co-cultured with Annexin A2 peptides and their corresponding control peptides 
was investigated. The results show decreased MMP-3 activity in C6-13 glioma secretome that has 
been treated with Annexin A2 peptides compared to secretome that was treated with control or no 
peptides. 
3.5.2 Effect of Annexin A2-S100A10 inhibition on MMP-3 expression 
To test the hypothesis that Annexin A2 peptides will inhibit MMP-3, the MMP3 expression was 
monitored by SDS-PAGE western blot. MMP-3 expression was shown to be down-regulated in 
C6-13 cells co-cultured with Annexin A2 peptides. Curiously, secretome from cells treated with 
scrambled peptide 1 (negative control peptide: HSLVLKEGILTSCE) significantly suppresses 
MMP-s activity and expression resembling peptide 1 effects (Figures 3.7and 3.8). In all, these 
results indicate that disruption of Annexin A2-S100A10 protein complex exerts a negative 






Figure 3.7 Annexin A2 peptide: MMP-3 zymography. 
MMP-3 activity analysis of Annexin A2 peptide treated cells and scrambled control were analyzed by zymography. Untreated cell 


















Figure 3.8 Annexin A2 peptide: MMP-3 western blot analysis 
MMP-3 expression analysis of Annexin A2 peptide treated cells and scrambled control were also analyzed by SDS-PAGE and proteins 
transferred to PVDF membrane were probed with rabbit monoclonal primary MMP-3 antibody. Untreated cells (black bar) received no 





Chapter 4: Discussion 
 
Annexin A2 
Annexin A2 is a 36 kDa protein involved in several cellular processes including cancer cell 
migration, invasion, and adhesion (76). It is part of a large protein family comprising up to 160 
unique Annexin proteins (76). They are made up of a very diverse N-terminal domain and a 
relatively more conserved C-terminal domain forming the core of the protein (77). The N-terminal 
domain offers a binding site for S100A10 and tissue plasminogen activator (t-PA) proteins while 
the C-terminal sites are used to bind F-actin, heparin, and plasminogen (Figure 4.1A-C). The core 
portion of the C-terminal domain binds calcium and the cell membrane (78-80). Annexin A2 
binding substrates suggests its role in intercellular transport, protein interactions signaling cell 
division and migration, as well as in plasmin production. 
In the cytoplasm, free Annexin A2 is involved in exploiting lipid micro-domains for 
membrane trafficking. It is also involved in exocytosis, and endocytosis (81, 82). Annexin A2 and 
CD44 interaction are important for the formation of lipid rafts, which are subdomains of the plasma 
membrane with high concentrations of cholesterol and glycosphingolipids that interact with the 
cytoskeleton (83). Also, Annexin A2 and S100A10 protein complex interact with the cytoskeleton 
through F-actin binding, thus suggesting Annexin A2 play a role in cellular migration. The 
translocation of Annexin A2 to the cell surface is mediated by phosphorylation at residue 23 by 
src-like tyrosine kinase (72). Annexin A2 bound to the membrane mainly facilitates plasmin 
production by promoting fibrinolysis and anticoagulation effects through the binding of S100A10 
and t-PA (84). Furthermore, the effect of Annexin A2 on solid tumors may be explained from its 




The increased expression of Annexin A2 in cancer tissues versus normal tissues has been 
reported from many studies. Annexin A2 is reported to be up-regulated in pancreatic, colorectal, 
and brain cancers in a manner that is indicative of the progression of the tumor (86). However, 
there are conflicting results regarding the expression of Annexin A2 in head and neck cancers. For 
example, Alonso et al (87) found that Annexin A2 mRNA and protein levels were significantly 
down-regulated in poorly differentiated head and neck tumors. These facts highlight the need to 





Annexin A2 has also been found to be secreted, apart from being a membrane protein (72). 
Since it lacks a signal peptide, Annexin A2 secretion is thought to be through the non-classical 
Figure 4.1 Annexin A2 structure and peptides 
Annexin A2 protein sequence (A) with its first 14 amino acid residue (shown in red) corresponding to S100A10 binding site. Synthesized small 
peptides corresponding to Annexin A2-S100A10 binding motif provides competitive inhibition of this complex (B) and Annexin A2 protein 
structure showing N- and C- terminal domains and binding molecules (C). 
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secretory pathway (72). Evidence for Annexin A2 secretion has been found in conditioned media 
of co-cultured human keratinocytes and fibroblasts (88). Proteomics studies of the secretome of 
the gastric cancer cell line, SGC7901, found that Annexin A2 was secreted as a phosphoprotein 
(89). Several studies indicate the involvement of Annexin A2 in regulating cancer cell adhesion, 
invasion, proliferation, and migration (80, 90-92). Apart from the role Annexin A2 plays in 
remodeling the cytoskeleton, thereby paving the way for cell migration, it also activated the 
plasminogen activator system. Annexin A2 in complex with S100A10 can bind t-PA. t-PA, in turn, 
activates plasminogen, which enhances plasmin production, leading to the activation of MMPs 
which can degrade the ECM and increased cancer cell migration (73, 74). 
 
Annexin A2 interactions 
S100A10 is part of a large family of calcium-binding proteins consisting of 25 isoforms 
that range from 9-13 kDa in size (93). About 88% of these 25 genes are located on chromosome 
1q21 region that is very prone to genomic rearrangements, pointing to S100 proteins as important 
players in cancer development (93). Soluble S100A10 is involved mainly in homeostasis, 
phosphorylation, cell growth, migration and cytoskeleton interactions (93). Cytoskeletal 
remodeling has far-reaching implications for glioma migration. On the other hand, extracellular 
S100A10 play critical roles in cell surface receptor binding by exhibiting a cytokine-like behavior 
(93). Also, S100A10 is critical to cell surface signaling of angiogenesis (94). 
The uniqueness of S100A10 is in its ability to be locked in an open conformation. Annexin 
A2 binds to S100A10 to form a heterotetramer of two Annexin A2 units and two S100A10 proteins 
(95). On the cell surface, this complex is a key plasminogen receptor leading to the production of 
plasmin, a major protease involved in ECM degradation (94). Several studies have implicated the 
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essential role Annexin A2 plays in regulating cell cancer adhesion, invasion, proliferation, and 
migration. In breast cancer and endothelial cell types, for example, Annexin A2-S100A10 complex 
is involved in cell-to-cell adhesion indicating a role in cancer migration (94). These interactions 
study involved protein expression profiling of Annexin A2 and S100A10 n tissues obtained from 
breast cancer patients (94). 
Plasmin, a serine protease, is formed from the cleavage of the inactive plasminogen found 
in plasma and extracellular matrix (73). This cleavage occurs from the interaction of plasminogen 
activators (t-PA) with the inactive plasminogen, highlighting the interplay of coagulation factors 
and enzymes in the plasmin-plasminogen system (73). In the ECM, plasmin degrades fibrin either 
by direct binding or in association with other activated proteases (74). The Plasmin-plasminogen 
system is critical to regulating ECM proteolysis, tissues remodeling, macrophage migration, 
invasion and angiogenesis (73). Tumor migration and invasion is enhanced by the upregulation of 
plasmin in the tumor microenvironment. Annexin A2 speeds up plasmin production, with the 
resultant effect of increased ECM proteolysis, by specifically having independent binding sites for 
t-PA and plasminogen (Figure 4.2). In several types of normal cells and cancer cells, Annexin A2-
S10010A exerts control over 50-90% of plasmin production (73). 
Human epididymis protein 4 (HE4) and Annexin A2 are involved in the activation of 
extracellular signal-regulated kinase/mitogen-activated protein kinase (ERK/MAPK) and focal 
adhesion kinase (FAK) signaling pathways (96). While the ERK/MAPK pathway signals 
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proliferation, migration, and apoptosis, the FAK pathway influences cell movement, invasion and 




Lysosomal procathepepsin B can facilitate tumor migration and invasion by degrading ECM 
proteins such as laminin, fibronectin and collagen IV (98). The Annexin A2-S100A10 
heterotetramer has been shown to interact with recombinant procathepsin (98). By acting on its 
Figure 4.2 Annexin A2 involvement in glioma migration 
Annexin A2 is trafficked to the cell surface by calcium binding and phosphorylation where it forms a heterotetramer with S100A10. 
Upregulation of Annexin A2 leads to the binding of t-PA and subsequent production of plasmin. Plasmin, in turn activates MMPs to 




own or through interaction with Annexin A2, procathepepsin can activate other ECM degrading 
proteins such as urokinase-type plasminogen activator and collagenase (98). 
The Kaplan-Meier survival plots for glioma (Figure 4.3A) shows a decrease in survival 
rate for patients with high EGFR expression when compared to patients with lower EGFR levels 
(99). High levels of EGFR is expected, as cancer biomarker. However, when compared to EGFR, 
the chances of survival for glioma patients with a high expression of Annexin A2 (99) was 
significantly reduced (Figure 4.3B). In glioma cells, upregulation of Annexin A2-S100A10 
complex, on the plasma membrane, has been proposed to activate t-PA binding which in turn leads 
to overproduction of plasmin, a serine protease, from plasminogen. Plasmin stimulates the action 
of other MMPs leading to ECM is degradation and the resultant increase in cell migration (100). 
Despite the progress made in defining the exact roles Annexin A2 play in glioma cell migration 
and invasion, and how these contribute to patient’s survival, a lot is still largely unknown and 







4.1 Differential centrifugation coupled with mass spectrometry (DC-MS) 
provides a robust high through-put validation of protein networks  
The development of new techniques and biological databases has resulted in a large turnout of 
protein-protein interaction data. A large portion of these PPI data is derived from mass 
spectrometry-based experiments such as affinity purification-mass spectrometry (AP-MS), a 
commonly used technique investigating protein interactions (50, 51). However, these PPI data are 
often generated as a list of proteins, which still requires that actual interactions be assigned between 
these proteins. The problem has always been that these PPI data are not often thoroughly validated. 
For instance, a single MS-based PPI experiment identifying 100 proteins would require 100 
validations (101, 102). In reality, only 1- 5 proteins that are most critical for the experiment may 
Figure 4.3 Glioma survival plots 
Kaplan-Meier plots for EGFR (A) and Annexin A2 (B). EGFR expression is a well-establish cancer biomarker, with a high expression reflecting 
a low chance of patient survival. The survival plots for EGFR and Annexin A2 show a further decrease in percent survival for patients with high 
Annexin A2 expression compared to EGFR. Plots were obtained for 329 out of 523 patient samples. P < 0.05 for reported plots (99). 
 
EGFR Annexin A2 
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be validated (102). This cherry-picking approach can be eliminated using the protein network 
validation strategy presented in this thesis. 
PPIs can be validated more efficiently and with a larger coverage of the dataset using 
differential centrifugation that is coupled to mass spectrometry. In this technique, protein 
complexes are enriched for subcellular locations by co-sedimenting the protein interacting 
partners. The list of identified proteins from the DC-MS procedure is then used to validate the 
candidate PPI list via functional analysis. However, this method needs to be further optimized and 
benchmarked for different experiments. The AP-MS Cx43 interaction data and the gap junction-
enrichment membrane protein complexes contained 110 and 1680 protein respectively (Figure 
3.1A). Gap junction enrichment was validated by western blot analysis (Figure 3.4). In this case, 
using a combination of protein ID comparison, protein enrichment analysis, and network clustering 
tools, 56 interacting proteins localized to the plasma membrane were extracted from the AP-MS 
Cx43 dataset. 
The LC-MS can be applied to other subcellular locations for validation of PPIs. For 
example, the centrifugation steps can be optimized for other subcellular locations. The protein list 
generated from the identified proteins can then be processed with the list of proteins to be 
validated. Ideally, for whole cell extracts, DC-MS can be performed multiple times to generate a 
complex interaction map. This method allows the user to generate a quick but robust snapshot of 
protein networks validation. It is also very useful where there is need to analyze previously 
acquired or archived data. Furthermore, DC-MS delivers the high-throughput orthogonal 
advantage of validating large datasets. 
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4.2 Annexin A2 is upregulated in glioma cells overexpressing Cx43 
The results from quantitative proteomic and western blot analysis demonstrate Annexin A2 
upregulation in C6-13 cells. For the protein quantification data, lysates from C6 and C6-13 cells 
were isotopically labeled by reductive dimethylation to ensure reliability and accuracy of 
downstream data analysis. Thus, only labeled peptides were included in the analysis. 
Chromatograms were extracted for labeled peptides in Skyline, and their intensities were 
quantified (Figure 3.3E). 
Western blot analysis further validates the upregulation of Annexin A2 in C6-13 gliomas 
which supports the results obtained from quantitative data (Figure 3.4). Annexin A2 play different 
roles in the cell depending on the cellular location. Since Annexin A2 binds S100A10 on the 
plasma membrane surface, the focus was to investigate its expression in gap junction-enriched 
plasma membrane relative to control cells. However, Annexin A2 expression was also examined 
in whole cell lysate (WCL) and cytosol. Annexin A2 in C6-13 cells was determined to be 
distributed more to the plasma membrane, at almost two times more than cytosolic Annexin A2. 
In wild type glioma, Annexin A2 expression was fairly equal across the plasma membrane, WCL, 
and cytosol. PVDF membrane were probed with Cx43 antibody demonstrate the enrichment of 
gap junctions. Cx43 was determined to be highly enriched in C6-13 plasma membrane fraction 
while GAPDH expression was diminished suggesting an enrichment for membrane proteins. The 
absence of Cx43 bands in the PM membrane fraction of C6 wild type cells, as well as the other 
fraction, maybe be explained by the very low expression or due to their high turnover rate.  
Annexin A2 expression in C6-13 WCL compared to the control cells followed the same trend as 
for plasma membrane. However, this overexpression was statistically insignificant. Many 
experiments geared towards studying differential expression of proteins have often relied on whole 
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cell extracts even when membrane proteins are involved. The results from this study determined 
that Annexin A2 is upregulated in C6-Cx43 glioma cells and that plasma membrane enrichment 
was critical to getting accurate results. The upregulation of Annexin A2 supports the notion that it 
is induced by the overexpression of Cx43 since up-regulation of both proteins tends to enhance 
glioma cell migration. 
4.3 Annexin A2-IP of C6-13 lysates reveals functional interaction between Cx43 
and Annexin A2 
Cx43 is a 43 kDa integral membrane protein that is synthesized in the endoplasmic 
reticulum and shipped to the Golgi apparatus where they are packaged into hemi-channel structures 
known as connexons (19, 21). These structures are then transported to the plasma membrane where 
they form gap junction sites (20). Intracellular Annexin A2 is trafficked to the plasma membrane 
surface by calcium ion binding and Tyr23 phosphorylation (72). Both Cx43 and Annexin A2 are 
similarly exposed to PTMs, notably phosphorylation by kinases as part of their regulation. The 
understanding of the protein interactions existing between these proteins will help define the exact 
mechanisms involved in these processes. 
As discussed in previous sections above, A2 upregulation in C6-13 glioma cells was 
demonstrated by quantitative proteomic data and western blot experiments. This increase in 
Annexin A2 expression was thought to be activated by the overexpression of Cx43 in these cells. 
To investigate the functional interaction between Annexin A2 and Cx43, C6-13 cell lysate was 
subjected to Annexin A2 IP and precipitated proteins were probed for Cx43. It was determined 
that Cx43 was co-complexed with Annexin A2 from the Annexin A2-IP proteins. Interestingly, 
there was an appreciable difference in the appearance of Cx43 protein bands from the lysate 
compared to that of Annexin A2-IP Cx43 probe protein (Figure 3.5). Cx43 is often phosphorylated 
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at multiple sites by kinases, resulting in shifts in migration on SDS-PAGE, usually between 37-45 
kDa (51). While Cx43 bands from the lysate (positive control) appear as a single band, heavy 
multiple phosphorylated bands were detected for the Annexin A2-IP Cx43 probe. These 
phosphorylated bands Cx43 phosphorylation at the plasma membrane closely resembling the Cx43 
bands obtained for gap junction enrichment western blot analysis (Figure 3.4). This suggests that 
the interaction between Cx43 and Annexin A2 occurs on the cell surface. 
Annexin A2 and Cx43 homology analysis also reveal several conserved sites that may 
contribute to the understanding of the exact binding patterns of the Annexin A2/Cx43 complex. 
Hydrophobic amino acids such as leucine and valine are usually abundant at protein-ligand 
interactions (103, 104). This binding of hydrophobic side groups is even more enhanced by the 
removal of water in the environment (105). For the Cx43/Annexin A2 homology analysis, most of 
the conserved areas contain leucine, isoleucine, valine as well as other residues that would readily 
form hydrophobic patches. Based on the strength of the evidence from the data that has been 
obtained so far, it can be proposed that Cx43 overexpression activates the increased expression of 
Annexin A2 which in turn signals Annexin A2-S100A10 binding. Annexin A2-S10010 complex 
then recruits t-PA that results in the overproduction of plasmin which then activates MMPs to 
degrade and remodel the ECM. 
4.4 MMP-3 overexpression in C6-13 cells supports this well-established model 
of glioma migration 
C6-13 gliomas provide a model for studying glioma migration. It is thought that since 
overexpression of Cx43 in this model system enhances glioma migration, there must be a 
corresponding increase in proteases that destroy the ECM, allowing migrating cells to escape to 
healthy brain tissue. MMPs are overexpressed in gliomas compared to the healthy brain with 
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MMP-2 and MMP-3 interacting with pro-migratory factors. It has been reported that MMP-3 in 
gliomas are involved in invasion where they are overexpressed. In light of the above, the 
expression of MMP-3 in gliomas overexpressing Cx43 was investigated relative to the wild type. 
Also, Annexin A2 has been reported to be secreted thereby providing a further interest in 
investigating the secretome for MMP-3 activity. The data obtained from MMP-3 gelatin 
zymography was supported by western blot analysis and demonstrates that while MMP-3 is 
overexpressed in glioma cells, it is upregulated even further in gliomas overexpressing Cx43. 
Ideally, casein is the preferred substrate for MMP-3 zymography detection suggesting that MMP-
3 was significantly up-regulated to be easily detected in gelatin. However, western blot analysis of 
the secretome confirms MMP-3 bands at the same position, ̴ 54 kDa. 
4.5 Disruption of Annexin A2-S100A10 complex significantly down-regulates 
MMP-3 activity and expression in C6-13 glioma cells 
At this point in this study, our experiments demonstrate a functional correlation between 
Cx43, Annexin A2 and MMP-3. The CoIP data reveals a functional interaction between Annexin 
A2 and Cx43, leading to the activation of proteases that degrade the ECM. Thus, the effects of 
Cx43/Annexin A2 interaction on MMP-3 activity and expression was investigated. Annexin A2-
S100A100 binding was competitively inhibited by small Annexin A2 peptides corresponding to 
the S100A10 binding motif on Annexin A2. Secretomes were analyzed for MMP-3 expression 
following peptide treatments along with untreated and scramble peptide controls. The results from 
MMP-3 zymography and western blot probe for MMP-3 demonstrates a down-regulation of MMP-
3 activity and expression in C6-13 secretomes treated with Annexin A2 peptides relative to the 
cells treated with scrambled peptides and the non-treated cells. However, as noted previously the 
scrambled peptide 1 also induced MMP-3 down-regulation, suggesting that it is able to inhibit 
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S100A10 binding with portions of its motif that may be involved in Annexin A2 or S100 A10 
binding (Figures 3.7 and 3.8). Homology analysis of scramble 1 (negative control peptide: 
HSLVLKEGILTSCE) was performed to try to explain the binding of this peptide and its ability to 
downregulate MMP-3 expression as shown in the functional analysis above. Since scramble 1 
peptide behaved much like the test peptides 1 and 2, they should all display similar binding 
patterns. As shown in Figure 4.4A-C, the S100A10 C-terminal -LSL- motif is conserved for 
scramble 1 and the test peptides. However, the control peptide, scramble 2 lacks the conserved 
region (Figure 4.4D).  
The conservation of hydrophobic residues, especially leucine is shown for S100A10, 
scramble 1 peptide, and Cx43 in Figure 4.4E. This further shows that Cx43 may not only interact 
with Annexin A2 directly, but also by interacting with S100A10 in the Annexin A2-S100A10 
tetramer. The binding of scramble 1 peptide to S100A10 may also be explained by the conserved 
cysteine residues (Figures 4.4C and 4.4E). The presence of a cysteine residue in scramble peptide 
1 may also account for its ability to block S100A10-Annexin A2 complex by forming disulfide 
bridges. There is therefore the possibility of establishing this peptide as a novel Annexin A2 
inhibitor, providing a means for further functional studies and development. The actions of 
Annexin A2 peptides can potentially be exploited and developed as tools for studying the 
mechanisms involved in glioma migration systems across several applicable experimental models. 






Figure 4.4 Homology modeling for Scramble 1 (HSLVLKEGILTSCE) small peptide. 
The binding of scramble 1 peptide was explored by performing homology analysis of S100A10 with (A) Peptide 2, (B) Peptide 1, (C) 
Scramble 1 and (D) scramble 2. The C-terminal -LSL- motif for S100A10 appears to be conserved for scramble 1 as is for Peptides 1 and 
2. However, scramble 2 lacks this conserved region. This motif is also conserved in Cx43 (E). Conserved cysteine residues (C and E) may 
also account for scramble 1 binding by forming disulfide bridges and blocking S100A10-Annexin A2 complex formation. 
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Chapter 5: Conclusion 
5.1 Thesis summary 
GBM is a WHO stage IV highly lethal type of brain cancer with a median patient survival 
of only about 14 months. The development of better treatment options, through the identification 
of new biomarkers and therapeutics, requires a thorough understanding of the signaling pathways 
involved in gliomas. This thesis sought to investigate further the contributions of protein-protein 
interactions of Cx43 to glioma migration, for which opposing roles have been reported previously. 
Proteomic quantitation data and western blot analysis reveals the upregulation of Annexin A2 in 
fast-moving gliomas, referring to C6 glioma cells that are overexpressing Cx43, relative to the 
slower control glioma cells. This thesis established a functional interaction between Annexin A2 
and Cx43 based on network analysis of previous Cx43 interaction data, Co-IP, and western blot 
validations. It was also demonstrated by zymography and western blot analysis that MMP-3 was 
upregulated in fast moving (C6-13) gliomas. 
Furthermore, the functional analysis of C6-13 secretome, treated with N-terminal Annexin 
A2 peptides, showed down regulation of MMP-3 activity and expression. This work is the first to 
validate the upregulation of Annexin A2 in C6-13 gliomas. It also the first to show evidence for 
the functional interaction of Annexin A2 and Cx43, as well as the first to validate Cx43 AP-MS 
data using high-throughput orthogonal methods. 
5.2 Future directions 
This thesis has investigated Cx43 protein interactions in glioma migration by first applying 
orthogonal high-throughput differential centrifugation methods to validate protein networks. Even 
though this method was used for enriching and validating gap junction-associated plasma 
membrane proteins, it can be applied to other subcellular locations. Since integrins are involved in 
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the structural connection of the ECM to the cytoskeleton, it may be useful to explore their role in 
the glioma model used for this study. Interestingly, integrins appear to be enriched in the previous 
analysis as well. Functional studies using Annexin A2 peptides should be extended to multiple cell 
lines as these peptides offer the immediate benefit of being used as functional analytic tools as 















Chapter 6: Markerglow: A simple, cost-effective tool for annotating 
protein molecular weight markers in western blots 
Western blotting is a widely used technique for the analysis of proteins in biochemistry and 
molecular biology (106). Proteins are first separated by sodium dodecyl sulfate polyacrylamide 
gel electrophoresis (SDS-PAGE) in tris-glycine running buffer and then transferred to a membrane 
where they are immobilized and probed with antibodies (106, 107). The transfer of proteins to a 
membrane and subsequent detection with antibodies provides a means of characterizing a 
multitude of proteins especially with proteins with low abundance (106, 107). There are several 
specific advantages that western blotting provides. The ease and pliability in handling wet 
membranes, different ligands readily and easily access proteins on the membrane, transfer analysis 
requires small reagents, a single membrane can be reprobed and investigated multiple times, and 
analysis is very reproducible (106, 108). 
Protein molecular weight markers are used in western blot analysis to estimate the relative 
molecular weight of proteins of interest. To this end, they are separated alongside the protein 
sample to be analyzed. The bulk of the commercially available protein molecular weight markers 
contain proteins that are prestained with vinyl sulfone dyes (108). This dye, commonly known by 
the trademark name, Remazol, provides visible reference points for the proteins to be identified 
(108). Proteins of interest are visualized by using specific antibodies that are linked to enzymes or 
fluorophores and produce chemiluminescence upon reaction with a substrate. Horseradish 
peroxidases are very widely used in western and in the presence of luminol produces 
chemiluminescence that can be detected on X-ray film or captured by CCD-based cameras (106, 
108). The main advantage of chemiluminescence is its sensitivity to detecting low amounts of the 
target proteins due to an enhanced signal from the enzyme-catalyzed reaction. However, the 
Remazol stained protein molecular weight markers are not detected by the X-ray or CCD-camera 
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capture, and as such, they are usually manually charted on the membrane or x-ray film and 
overlayed on the CCD-camera capture (108). This often prone to errors form imperfect alignment 
and theses inaccuracies is also directly affects the interpretation of data. 
 All of the currently available tools to visualize protein molecular weight markers have 
several setbacks and disadvantages. Thus, there is a limitation to their usage. There are current 
luminol based pens available, such Optiblot Luminol Pen (Abcam) and WestenSure Pen (LiCor) 
are easy to use but are relatively expensive (108). This especially so for laboratories routinely 
utilizing western blot analysis and need to continuously scan and rescan protein blots. Detection 
of target proteins also requires that blot be scanned to detect chemiluminescence, and this often 
require very expensive scanner like LI-COR Odyssey, or GE Typhoon (108). 
Markerglow is a simple and cost-effective tool for visualizing molecular weight markers. 
It offers several advantages and solutions to some of the problems currently facing the effective 
visualization of proteins markers. It is made from relatively basic everyday materials and take 
minutes to make and ready to use. Markerglow is a very small fraction of the cost compared to 
available commercial products. It is very reproducible and marked membranes can be re scanned 
multiple times. It also does not need any substrate as it is based on phosphorescence and needs just 
a brief exposure to a good light source. 
6.1 Markerglow preparation 
To prepare Markerglow, glow dust (Winlow) and basic cream nail polish were purchased. In a 
small ceramic mortar, 1g of glow dust was blended to obtain a very fine powder, and about 500 -
750 mg of the blended glow dust was added to 15 ml of cream nail polish to about 3.3 – 5% glow 
dust concentration (w/v). However, this needs to be optimized for the desired glow intensity and 
signal detection equipment to be used. In this case, a Li-COR C-DiGit blot scanner was used. The 
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glow dust and nail polish were then completely mixed by shaking vigorously to obtain the final 
product. 
6.2 Application on PVDF membrane 
Markerglow was applied to the protein side of the PVDF membrane. It can be applied as clean 
small circular spots on the middle of the molecular weight markers or by carefully applying it to 
the entire length of the protein marker bands. To obtain best results, excess marker glow on the tip 
of the brush used for spotting should be removed by brushing against the nail polish walls a couple 
of times. The wet PVDF membrane is removed from the wash buffer after secondary antibody 
incubation and placed on saran wrap. A small piece of Kim wipe was folded and used to gently 
remove excess wash buffer on the protein molecular weight marker lane, while leaving all other 
areas of the membrane as wet as possible. The molecular weight marker bands were then gently 
spotted as clean as possible with Markerglow. The membrane was then exposed to light for 1- 
3mins to dry and charge the Markerglow spots, taking care not to let the rest of the membrane dry 
out.  
6.3 PVDF membrane scan 
Spotted PDVF membrane was incubated in 1ml ECL reagents for about 1 minute and immediately 
transferred to the LI-COR C-DiGit scanner. The membrane was placed with protein/Markerglow 
spot face down in the scanner. Membrane was scanned using the high sensitivity setting on the 
scanner. 
6.4 PVDF membrane stripping and re-scanning  
To investigate the effect of stripping on the signal intensity of Markerglow, the membrane was 
subjected to a stripping protocol using a mild stripping buffer (0.2M glycine, 0.1% SDS, 1% 
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Tween-20, pH = 2.2). Briefly, membrane was incubated in stripping buffer for 2 x 30 minutes each 
on a shaker set to gentle agitation. Stripping buffer was removed, and membrane was washed twice 
in 1X PBS for 10 minutes each, and then washed 2 x 5 minutes each in PBS-T. Membrane was 
then re-scanned as described previously. 
6.5 Results and Discussion 
Apart from being a simple and cost-effective solution to annotating molecular weight markers in 
western blot analysis, Markerglow provides the benefit of saving time as spotted membranes can 
be reprobed without the need to re-spot the marker bands during scanning. As Markerglow does 
not require ECL reagents to work, the spots become even more pronounced in re-scans due to 
continuous exposure to light (Figure 6.1). Furthermore, reprobing of blots that have already been 
spotted was shown not to interfere with the detection of target proteins. 
Figure 6.1 Markerglow annotation of western blot molecular weight markers 
Scanned western blots showing Markerglow annotation of a 10 – 175 range molecular weight marker resolved in 10% SDS-PAGE prior 
to transferring proteins to membrane. Only spotted bands are shown. Following initial Markerglow spotting and scanning on the 
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